In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adamas Pharmaceuticals Inc.

www.adamaspharma.com

Latest From Adamas Pharmaceuticals Inc.

Pharma Sourcing And Procurement: The New Strategy Of Spend

Just what does a strategic approach to sourcing and procurement mean for today’s biopharma enterprise? In Vivo talks to the practice leaders at two diversely representative companies – Adamas Pharmaceuticals and Roivant Sciences – to identify four essential characteristics of “best in class” purchasing performance: (1) Think big – be strategic. (2) Buy better – add value.  (3) Work fast – spend forward. (4) Reach out earn the business.

Business Strategies Growth

Pipeline Watch: Phase III Starts With Enzastaurin, Sparsentan And Abaloparatide

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals

Deals Shaping The Medical Industry, February 2018

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2018.

Deals Medical Device

Finance Watch: Another Mega-Round As Moderna Bucks Biopharma's IPO Trend

Moderna raised $500m to fund its growing pipeline, choosing once again to stay private rather than pursue an IPO. Also, AvroBio closed a $60m Series B round to advance its gene therapies for lysosomal storage disorders, Seattle Genetics led recent public company financings, and Vical is restructuring.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • NeuroMolecular Pharmaceuticals Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Adamas Pharmaceuticals Inc.
  • Senior Management
  • Gregory T Went, PhD, Chmn. & CEO
    Merriweather G Alfred, CFO
    Jennifer J Rhodes, CBO, Gen. Counsel, CCO & Corp.Sec.
    Rajiv Patni, MD, CMO
    Vijay Shreedhar, PhD, COO
  • Contact Info
  • Adamas Pharmaceuticals Inc.
    Phone: (510) 450-3500
    2200 Powell St.
    Ste. 750
    Emeryville, CA 94608
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register